Midazolam (MDZ) is a commonly used Benzodiazepine in clinical practice. In addition, its metabolic oxidation is used as a surrogate marker for Cytochrome P450 (CYP) 3A enzyme activity as well. Thus, a new simpler method to measure MDZ and its metabolites is welcomed. Herein we report a new and simple HPLC method with ultraviolet detection for the simultaneous determination of midazolam and its hydroxyl metabolites using lorazepam as an internal standard. A liquid-liquid extraction was used to extract the compounds from rabbit hepatic microsomes and human plasma. The separation was performed on a Zorbax Eclipse XDB C18 column using a mobile phase composed of 0.05M Na2PO4 (pH 4.5) and acetonitrile mixture (67:33) pumped at 1.2 mL/min. The calibration curves showed good linearity with correlation coefficient higher than 0.999 for all analytes in the range 10-500 ng/mL. Accuracy in the measurement of quality control (QC) samples was in the range 95-106% of the nominal values. The intra-day and inter-day precision in the measurement of QC samples were less than 11% coefficient of variation. Although less sensitive than gas-chromatography-mass spectrometry (GC-MS), the proposed method was adequately sensitive to measure midazolam hydroxylase activity as a marker for CYP3A activity, and was applied to measure midazolam pharmacokinetics in human plasma..
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HPLC INSTRUMENTATION
The HPLC system consisted of Waters model 2695 Alliance separation module, model 2996 photodiode array detector and Empower data module (Millipore-Waters, Milford, MA, USA). Chromatographic separation was carried out on Zorbax Eclipse XDB C18 column (150  4.6 mm I.D., 5 m particle size). The column was kept at 25°C.
CHROMATOGRAPHIC CONDITIONS
The isocratic mobile phase consisted of 0.05M Na 2 PO 4 (pH 4.5) adjusted with phosphoric acid) and acetonitrile mixture (67:33) was run at a flow rate of 1.2 ml/min. Absorbance was monitored at 227 nm. This wavelength was found adequate to monitor MDZ, 1-OH MDZ, 4-OH MDZ, and LOR as indicated by using the PDA detector.
METHOD VALIDATION
Method validation procedures were performed according to FDA guidelines (www.fda.gov/cder/guidance/cmc3.pdf, accessed on Feb 10, 2009) to evaluate the suitability of the method for the quantitative determination of MDZ and its metabolites in rabbit hepatic microsomes and MDZ alone in human plasma.
MEASUREMENT OF HEPATIC CYP3A ACTIVITY IN RABBITS
MDZ hydroxylase activity was determined by quantification of 1-OH MDZ and 4-OH MDZ formation rates in rabbit hepatic microsomes. Preliminary experiments were conducted to determine linear metabolite formation kinetics with respect to MDZ concentration, incubation time and microsomal protein concentration. 
PHARMACOKINETIC ANALYSIS
The maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) following MDZ administration were obtained directly from the individual plasma-concentration time data for MDZ. The area under concentration-time curve from time zero to infinity (AUCo-∞) was measured using linear trapezoidal summation with extrapolation. The terminal elimination rate constant (β) was estimated by linear least square regression analysis of the terminal log-linear portion of plasma-concentration time curve. The terminal elimination half-life (t 1/2 ) was determined as ln2/β.
RESULTS

Intercept
Slope R2 LLOQ LLOD Linearity range Rabbit Hepatic Microsomes Average* SD Average* SD Average* SD (ng/mL) (ng/mL) (ng/mL) 4-OH MDZ 0.0408 0.0059 0.005 0.0004 0.9993 0.00036 10 2.5 10-500 1-OH MDZ 0.0739 0.0014 0.0112 0.0009 0.9995 0.0003 10 2.5 10-500 MDZ 0.0812 0.0052 0.0185 0.0002 0.9994 0.0002 10 2.5 10-500 Human Plasma MDZ 0.0029 0.0095 0.0196 0.0017 0.9991 0.0009 10 5 10-500 * n = 6 Table 1 . Extraction recovery of MDZ, its metabolites and the internal standard (LOR) from spiked rabbit hepatic microsomes (n= 5), and extraction recovery of MDZ and LOR in spiked human plasma samples (n = 5). Table 2 . Linearity data for the quantification of MDZ in human plasma and MDZ and its metabolites in rabbit hepatic microsomes by the proposed HPLC method.
Cmax
Tmax AUC (0-∞) β t 1/2 (ng/mL) (hr) (ng.hr/mL) (hr-1) Table 3 . Intraday (n = 5) and inter-day (10 consecutive days) accuracy and precision data for the quantitation of MDZ in human plasma, and MDZ and its metabolites in rabbit hepatic microsomes by the proposed HPLC method. 
